Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GW642444 25 Clear all
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316900
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444, tiotropium bromide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316913
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719, tiotropium bromide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Jasper, Alabama • Mobile, Alabama • Huntington Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

NCT01691547
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC /VI, UMEC, VI, FF
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01316887
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719, Placebo once-daily
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 120 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Mobile, Alabama • Sunset, Louisiana • Plymouth, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

NCT01453296
View directory record Official record
Conditions
Asthma
Interventions
GW642444, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Cypress, California • Huntington Beach, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

NCT03248128
View directory record Official record
Conditions
Asthma
Interventions
FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
49
States / cities
Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

NCT01323660
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125, GSK573719 62.5, GW642444 25, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01879410
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

NCT01328444
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125, GSK 573719 62.5, GW642444 25, Plb
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Lebanon, New Hampshire • Albany, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01017952
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01009463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
94
States / cities
Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 14, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

NCT01894386
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 14, 2026, 1:38 PM EDT